Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series
Autor: | Rob Pieters, Erin H. Breese, Luciano Dalla-Pozza, Nicole Bodmer, Kjeld Schmiegelow, Christian M. Zwaan, Adriana Thano, Raoull Hoogendijk, Fanny Rialland, Christophe F Chantrain, Audrey Contet, Erica Brivio, Inna V. Markova, Krisztián Miklós Kállay, Motohiro Kato, Tanja A. Gruber, Sarah Elitzur, Chi Kong Li |
---|---|
Přispěvatelé: | Pediatrics, University of Zurich, Zwaan, Christian Michel |
Rok vydání: | 2021 |
Předmět: |
Male
Pediatrics medicine.medical_specialty Neoplasm Residual 2720 Hematology 610 Medicine & health Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Refractory hemic and lymphatic diseases Overall survival Humans Medicine Inotuzumab Ozogamicin Inotuzumab ozogamicin Series (stratigraphy) business.industry Hematopoietic Stem Cell Transplantation Complete remission Infant Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma Allografts Minimal residual disease Confidence interval Survival Rate 10036 Medical Clinic Child Preschool 030220 oncology & carcinogenesis Lymphoblastic leukaemia Female business 030215 immunology medicine.drug |
Zdroj: | British Journal of Haematology, 193(6), 1172-1177. Wiley-Blackwell Publishing Ltd |
ISSN: | 1365-2141 0007-1048 |
Popis: | No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified. |
Databáze: | OpenAIRE |
Externí odkaz: |